Advertisement
U.S. markets open in 4 hours 49 minutes

Incyte Corporation (INCY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
57.12+0.57 (+1.01%)
At close: 04:00PM EDT
57.10 -0.02 (-0.04%)
After hours: 05:21PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close56.55
Open56.50
Bid57.06 x 400
Ask57.18 x 400
Day's Range56.50 - 57.30
52 Week Range50.27 - 76.04
Volume1,463,986
Avg. Volume1,720,575
Market Cap12.825B
Beta (5Y Monthly)0.65
PE Ratio (TTM)21.55
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
14% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for INCY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Incyte Corporation
    The Argus Mid-Cap Model PortfolioSmall- and mid-cap stocks (SMID) have underperformed large-caps over the past 12 months, but may be in a better position to generate market-beating returns going forward. SMID companies tend to focus on domestic markets, so their businesses could be less disrupted by the fallout from global events. As well, the prices of SMID stocks generally are lower than the prices of large-caps. As well, there are long stretches in the record books when SMID stocks have outperformed large-caps. That said, SMID stocks can be risky. The standard deviation for monthly returns was 5.7% for SMID stocks over a 2003-2021 test period, versus 4.3% for large-caps. Still, despite the risks, diversified investors look to have exposure to small- and mid-caps based on the long-term performance record.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • Zacks

    Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up

    Mesoblast (MESO) gains as the FDA states that the available phase III data for lead candidate, remestemcel-L, is sufficient to support a regulatory filing for pediatric SR-aGVHD indication.

  • Bloomberg

    SEC Tests Insider-Trading Theory at Trial of Ex-Biotech Executive

    (Bloomberg) -- A lawyer for the US Securities and Exchange Commission told a jury that a former biotech executive’s $120,000 windfall on a trade in a competing company’s stock was “like betting on a game when you know who’s going to win” because he knew the pending takeover of his firm would likely boost its rival.Most Read from BloombergTrump’s Net Worth Hits $6.5 Billion, Making Him One of World’s 500 Richest PeopleBiden Gains Ground Against Trump in Six Key States, Poll ShowsTrump Vows to Pay

  • Insider Monkey

    30 Biggest Biotechnology Companies in the World

    In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United […]